BRAF and melanoma: Some of the biomarkers on circulating T cells showed a difference between groups at the before treatment time point, and we believe the reason for this is that these patients were diagnosed with different types of cancer and had previously received different chemotherapeutic agents in lung and renal cancer and target therapy for BRAF mutation in melanoma, which influenced the initial state of their immune systems.